Cas No. 1168150-46-6, (3E)-2,3-Dihydro-3-(methoxyphenylmethylene)-2-oxo-1H-indole-6-carboxylic acid methyl ester

Nintedanib is reshaping the treatment landscape of idiopathic pulmonary fibrosis, offering a much-needed therapeutic option for patients with this debilitating lung disease. With our reliable intermediates, streamline the manufacturing process and ensure a steady supply of this transformative medication. Join us in pioneering the fight against pulmonary fibrosis, improving patients' quality of life and driving innovative advancements in respiratory care. Embrace Nintedanib and make a lasting impact in the field of pulmonary therapeutics.